Vanguard Capital Management
MRKR icon

Vanguard Capital Management’s Marker Therapeutics MRKR Stock Holding History

Vanguard Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$626K Buy
426,169
+36,850
+9% +$53.7K ﹤0.01% 3676
2026
Q1 		$506K Buy
+389,319
New +$618K ﹤0.01% 3671

Other funds holding MRKR

BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Vanguard Capital Management's MRKR Position: Q2 2026 in Review

Vanguard Capital Management increased its Marker Therapeutics (MRKR) stake by 9.5% in Q2 2026, buying an estimated $53.7K and bringing the position to 426,169 shares worth $626K. The position accounts for ﹤0.01% of the portfolio, ranked #3676.

Vanguard Capital Management first reported a position in MRKR in Q1 2026 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

  • Vanguard Capital Management held 426,169 shares of Marker Therapeutics worth $626K as of Q2 2026.
  • Vanguard Capital Management bought 36,850 Marker Therapeutics shares in Q2 2026, an estimated $53.7K.
  • Marker Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3676 holding.
  • Vanguard Capital Management first reported a position in Marker Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.